Regulatory Action - French government fined Shein €40 million (approximately $43 million USD) due to deceptive promotional practices [1] Pricing Practices - 11% of Shein's advertised "discounts" involved price increases before the discount [1] - 57% of promotions did not involve an actual price reduction [1] - 19% of price reductions were less than advertised [1] Industry Impact - The findings by the French competition, consumption and anti-fraud authority (DGCCRF) highlight potential consumer protection issues within the fast fashion e-commerce sector [1]

Core Viewpoint - Investors with significant losses in Hims & Hers Health, Inc. have the opportunity to lead a securities fraud class action lawsuit against the company [1]. Group 1: Lawsuit Details - The lawsuit alleges that between April 29, 2025, and June 23, 2025, Hims failed to disclose that it was involved in the deceptive promotion and sale of illegitimate versions of Wegovy, which posed risks to patient safety [3]. - The complaint also claims that there was a substantial risk of termination of Hims' collaboration with Novo Nordisk due to these undisclosed actions [3]. - As a result of the aforementioned issues, the positive statements made by Hims regarding its business operations and prospects were materially misleading and lacked a reasonable basis [3]. Group 2: Participation Information - Investors who suffered losses in Hims & Hers Health, Inc. are encouraged to contact the Law Offices of Howard G. Smith before August 25, 2025, to participate in the ongoing lawsuit [2]. - Interested parties can reach out via email or phone to discuss their legal rights and options regarding the class action [4].

AI 时代的「最强」打工人出现了。 骗倒全硅谷，一人打几份工，拿 offer 拿到手软，引来 1375 万人的围观，并直接屠榜海外各大社交平台。 这事要从 Playground AI 的创始人 Sohail Doshi 今天在社交媒体上发的一条爆料说起。他表示，一位名为 Soham Parekh 的印度工程师，靠着一份几乎 90% 造假的简历，同时在 3-5 家初创公司上班。 Sohail Doshi 表示，入职第一周就发现对方不对劲，于是立马开除，临走前还苦口婆心地劝对方别再骗人了，没想到这位印度老哥非但没收手，还越战越 勇，继续多线作战。 打工人经常被资本做局是惯有的事，如今，资本被打工人明显地反向薅羊毛，还真是头一遭。随着事件热度飙升，YC 总裁 Garry Tan 也亲自下场发文表 示： 如果没有 YC 社区，这个人可能还在继续操作，甚至永远不会被发现。YC 的创业者联盟是一个非常必要的存在，它帮助创始人们比单打独斗时更容易取 得成功。 根据 Garry Tan 的说法，这位印度老哥专挑 YC 支持的创业公司下手，同时在至少三家由 YC 支持的创业公司打卡上班，最多甚至五家，并且每家公司都 以为他是全 ...

Core Viewpoint - Investors in Rocket Pharmaceuticals, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that from February 27, 2025, to May 26, 2025, Rocket Pharmaceuticals failed to disclose significant risks, including serious adverse events (SAEs) such as participant deaths in clinical studies [3]. - The complaint states that Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to misleading positive statements about the company's operations and prospects [3]. Group 2: Participation Information - Investors who suffered losses in Rocket Pharmaceuticals are encouraged to contact the Law Offices of Howard G. Smith before August 11, 2025, to participate in the ongoing lawsuit [2][4]. - Individuals interested in learning more about the class action or their rights can reach out to the law firm via email or phone [4][5].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased the company's debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

俗话说，酒香不怕巷子深，但这句话放在外汇零售行业不一定对。据外汇天眼监测的数据，大大小小的外汇交易商接近7万家，在白热化的竞争中不少平 台为了揽客在交易环境、客服支持、资金通道上做得出类拔萃，但无奈还是生意惨淡。究其原因，还是没有一块好的金字招牌。 外汇天眼官网"上市信息"显示，嘉伍佰分别在全球最大的金融中心伦敦证券交易所上市；另外，欧盟金融中心法兰克福也有嘉伍佰的上市股票。能同时登 陆两大顶级证券交易所，暗示着嘉伍佰这个品牌自身实力不俗。 | WikiEX EPP (0) 什么是WikiFX > | HIT = 10/4/9 | | 请输入交易商各称进行查询 | 搜索 | | 42 ● 简体中文 ◆ 下载WikiFX | | --- | --- | --- | --- | --- | --- | --- | | 营顾 交易商 | SkyLine ! Form For | 排行榜 监管机构 | VPS ~ | 第二十 | 社区 | = 曝光 ▼ 蛋開 > | | | | | | | | CLASS MENT PENSIONAL THE VILLED. | | | | 监管信息 | | × | | | | ■ ...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Compass Group Diversified Holdings, LLC ("Compass Diversified" or the "Company") (NYSE: CODI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Compass Diversified investors who were adversely affected by alleged securities fraud between February 24, 2022 and May 7, 2025. Follow the link below to get more information and be contacted by a member of our team: https:// ...

当地时间6月30日，美国司法部表示，已制止一系列试图从联邦政府骗取146亿美元的医疗保健欺诈案。 司法部称，该案是美国历史上规模最大的医疗保健欺诈行动。司法部对324名被告提起了刑事指控，并 扣押超过2.45亿美元的现金、豪华汽车和其他资产。官员表示，美国政府实际损失约29亿美元。(央视 新闻) ...

黄永翔，深圳市高德信通信股份有限公司董事、副总经理、董事会秘书。 文/梧桐小新 6月27日，北交所公布了对深圳市高德信通信股份有限公司（高德信，832645）及相关主体纪律处分的决 定，因高德信公开发行文件引用的财务数据存在虚假记载，存在编造重大虚假内容的情形，2018年至2021 年分别虚增营业收入6,007.36万元、12,386.59万元、13,766.04万元、12,950.53万元，占当期披露营业收入的 比例分别为38.11%、59.77%、75.26%、63.27%。北交所决定给予高德信公开谴责、五年内不接受其提交的 发行上市申请文件的纪律处分。 同时，公司时任董事长黄永权也被北交所给予公开谴责，五年内不接受黄永权控制的其他发行人提交的发 行上市申请文件，认定黄永权五年不适合担任上市公司董监高的纪律处分；其他相关责任人员同样受到公 开谴责的纪律处分。 而在今年1月13日，高德信已因财务造假、欺诈发行被深圳证监局处罚，高德信被处以1000万元罚款，5名 相关责任人被处以150万元到1300万元不等合计2270万元的罚款，黄永权被采取5年证券市场禁入措施。 延 伸阅读： 《又一财务造假、欺诈发行被重罚 ...

Group 1 - The National Medical Insurance Administration has announced the full implementation of drug traceability codes starting July 1, which will serve as an "electronic ID" for drugs, requiring medical institutions to record and trace information throughout the entire process of drug payment [1][2] - Medical institutions and retail pharmacies must accurately collect and verify drug traceability codes and upload this information to a national unified medical insurance information platform and drug traceability system [1][2] - A special action has been initiated to combat fraud and illegal activities in the pharmaceutical sector, with the first phase of inspections already completed and a new round of checks scheduled for August [1] Group 2 - The traceability code is a key factor in establishing verification and acceptance systems for drug procurement, and institutions are urged to avoid accepting or trading in returned drugs [2]